Novel Compound Heterozygous Variants in Trans-2,3-Enoyl-Coenzyme A Reductase-Like Gene Associated With Catecholaminergic Polymorphic Ventricular Tachycardia
Open Access
- 7 May 2024
- journal article
- case report
- Published by Elsevier in JACC: Case Reports
- Vol. 29 (11) , 102364
Abstract
No abstract availableKeywords
Funding Information
- Japan Agency for Medical Research and Development
This publication has 10 references indexed in Scilit:
- Transcriptome analysis of effects of Tecrl deficiency on cardiometabolic and calcium regulation in cardiac tissueOpen Medicine, 2024
- Trans‐2,3‐enoyl‐CoA reductase‐like‐related catecholaminergic polymorphic ventricular tachycardia with regular ventricular tachycardia and response to flecainideJournal of Cardiovascular Electrophysiology, 2023
- Novel trans-2,3-enoyl-CoA reductase–like variant associated with catecholaminergic polymorphic ventricular tachycardia type 3HeartRhythm Case Reports, 2022
- European Heart Rhythm Association (EHRA)/Heart Rhythm Society (HRS)/Asia Pacific Heart Rhythm Society (APHRS)/Latin American Heart Rhythm Society (LAHRS) Expert Consensus Statement on the state of genetic testing for cardiac diseasesJournal of Arrhythmia, 2022
- Life-threatening arrhythmias with autosomal recessive TECRL variantsEP Europace, 2020
- Novel variants in TECRL cause recessive inherited CPVT type 3 with severe and variable clinical symptomsJournal of Cardiovascular Electrophysiology, 2020
- A compound heterozygosity of Tecrl gene confirmed in a catecholaminergic polymorphic ventricular tachycardia familyEuropean Journal of Medical Genetics, 2019
- TECRL, a new life‐threatening inherited arrhythmia gene associated with overlapping clinical features of both LQTS and CPVTEMBO Molecular Medicine, 2016
- A Novel Early Onset Lethal Form of Catecholaminergic Polymorphic Ventricular Tachycardia Maps to Chromosome 7p14‐p22Journal of Cardiovascular Electrophysiology, 2007
- GeneReviews®1993